Labeling Is Critical As Bump From Compendia Listing Diminishes – Genentech
Executive Summary
Listing off-label uses in compendia may no longer provide the same bump in sales that would have been seen in the past, Genentech Exec VP - Commercial Operations Ian Clark said
You may also be interested in...
Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials
FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman
Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials
FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman
Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use